Thomas Large, CEO and Co-Founder, has broad leadership experience in biopharma spanning R&D, regulatory and new product planning functions as well as M&A, corporate integration and investor relations. He has a successful track record of partnering with large pharma, biotech, CRO, academic and government organizations. Tom is a recognized leader in the systems neurobiology of brain disorders and pioneering new paradigms for CNS drug discovery and development. At Eli Lilly, he implemented innovative research approaches in neuroscience as well as oncology and endocrine therapeutic areas. At Sepracor/Sunovion, his discovery and translational medicine group delivered multiple clinical drugs with modes-of-action distinct from existing CNS drug classes, including SEP-363856, a novel antipsychotic drug recently recognized by the FDA as a Breakthrough Therapy. His honors include President’s and Alliance awards at Eli Lilly, Spirit of Innovation award at Sunovion and PhRMA representative to the White House Precision Medicine Initiative.
Tom earned a Ph.D. in Neurobiology at Northwestern University, was a Howard Hughes postdoctoral scholar at UCSF and a member of the Neuroscience Dept. at Case Western Reserve Medical School.